p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 16, 2014, Pages

  McFadden, David G ^a,b   Vernon, Amanda ^a   Santiago, Philip M ^a   Martinez McFaline, Raul ^a   Bhutkar, Arjun ^a   Crowley, Denise M ^a   McMahon, Martin ^b   Sadow, Peter M ^c   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaplastic thyroid cancer; Genetically engineered mouse model; Mek inhibitor; Vemurafenib

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN P53;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR INVASION;

ANAPLASTIC THYROID CANCER; GENETICALLY-ENGINEERED MOUSE MODEL; MEK INHIBITOR; VEMURAFENIB;

ANIMALS; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; NEOPLASM GRADING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898411721     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404357111     Document Type: Article

References (36)

1. Cooper DS, et al.; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167-1214.
2. Smallridge RC, et al.; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104-1139.
3. Ricarte-Filho JC, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885-4893.
4. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI (2008) Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-284.
5. Fagin JA, et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91(1):179-184. (Pubitemid 23037270)
6. Ito T, et al. (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52(5):1369-1371.
7. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569-580.
8. Gauchotte G, et al. (2011) BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis. Pathology 43(5):447-452.
9. Chakravarty D, et al. (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121(12):4700-4711.
10. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M (2011) Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71(11):3863-3871.
11. Franco AT, et al. (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108(4):1615-1620.
12. Knauf JA, et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65(10):4238-4245. (Pubitemid 40775662)
13. La Perle KM, Jhiang SM, Capen CC (2000) Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157(2):671-677. (Pubitemid 30626925)
14. Antico Arciuch VG, et al. (2011) Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2(12):1109-1126.
15. Sherman SI (2011) Targeted therapies for thyroid tumors. Mod Pathol 24(Suppl 2): S44-S52.
16. Montero-Conde C, et al. (2013) Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3(5):520-533.
17. Kim KB, et al. (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23(10):1277-1283.
18. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S (2004) Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39(3):212-216. (Pubitemid 39079520)
19. Dankort D, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21(4):379-384.
20. Orim F, et al. (2014) Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model. Thyroid 24(3):502-510.
21. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550. (Pubitemid 41528093)
22. Knauf JA, et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30(28):3153-3162.
23. Wenig BM (1993) Atlas of Head and Neck Pathology (Saunders, Philadelphia).
24. Hou P, Ji M, Xing M (2008) Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113(9):2440-2447.
25. Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368(7):684-685.
26. Flaherty KT, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694-1703.
27. Faustino A, et al. (2012) mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 97(7):E1139-E1149.
28. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW (2011) Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17(20): 6482-6489.
29. Guerra A, et al. (2012) The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97(2):517-524.
30. Shimamura M, et al. (2013) Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma. Endocrinology 154(11):4423-4430.
31. Nehs MA, et al. (2012) Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 153(2):985-994.
32. Nucera C, et al. (2011) Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16(3):296-309.
33. Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20(1):87-90.
34. Pohlenz J, et al. (1999) Improved radioimmunoassay for measurement of mouse thyrotropin in serum: Strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid 9(12):1265-1271. (Pubitemid 30038940)
35. Gentleman RC, et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5(10):R80.
36. Charles RP, Silva J, Iezza G, Phillips W, McMahon M (2014) BRAF(V600E) cooperates with PIK3CA(H1074R) to promote anaplastic thyroid carcinogenesis. Mol Cancer Res, in press.